• 1
    Roupret M, Yates DR, Comperat E et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 2008; 54: 12261236
  • 2
    Skeldon SC, Semotiuk K, Aronson M et al. Patients with lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013; 63: 379385
  • 3
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919932
  • 4
    Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 18511860
  • 5
    Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848855
  • 6
    Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247257
  • 7
    Sinicrope FA, Foster NR, Thibodeau SN et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863875
  • 8
    Audenet F, Yates DR, Cussenot O et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 2013; 31: 407413
  • 9
    Hellenthal NJ, Shariat SF, Margulis V et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009; 182: 900906
  • 10
    Vassilakopoulou M, de la Motte Rouge T, Colin P et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011; 117: 55005508
  • 11
    Audenet F, Colin P, Yates DR et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int 2012; 110: E583589
  • 12
    Ouzzane A, Colin P, Xylinas E et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 2011; 60: 12581265
  • 13
    Berod AA, Colin P, Yates DR et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int 2012; 110: E10351040
  • 14
    Tejpar S, Saridaki Z, Delorenzi M et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 2011; 103: 841844
  • 15
    Buecher B, Cacheux W, Rouleau E et al. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 2013; 45: 441449
  • 16
    Birtle AJ, Lewis R, Johnson M et al. Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) – opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial. BJU Int 2012; 110: 919921
  • 17
    Meeks JJ, Bellmunt J, Bochner BH et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62: 523533
  • 18
    Kaag MG, O'Malley RL, O'Malley P et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010; 58: 581587
  • 19
    Kim JE, Hong YS, Ryu MH et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci 2011; 102: 17061711
  • 20
    Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 32193226
  • 21
    Xylinas E, Rink M, Margulis V et al. Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. Eur Urol 2012; 62: e2526
  • 22
    Roupret M, Zigeuner R, Palou J et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011; 59: 584594
  • 23
    Roupret M, Catto J, Coulet F et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J Med Genet 2004; 41: e91
  • 24
    Roupret M, Fromont G, Azzouzi AR et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005; 65: 12331237
  • 25
    Lindor NM, Burgart LJ, Leontovich O et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 10431048
  • 26
    Kuppermann M, Wang G, Wong S et al. Preferences for outcomes associated with decisions to undergo or forego genetic testing for Lynch syndrome. Cancer 2013; 119: 215225
  • 27
    Lynch HT, Lynch PM. Molecular screening for the Lynch syndrome–better than family history? N Engl J Med 2005; 352: 19201922